Why is Abivax stock climbing today?
Abivax ($ABVX) is climbing today and nobody's handed me a clean reason yet, which usually means it's an early-stage biotech headline — data, a filing, an analyst flip. My read: traders are treating it as a momentum name again, and biotechs with a single pipeline asset move hard on sentiment because there's no earnings floor to argue over.
The bullish case is flow — small-cap biotech has been a hunting ground whenever rate-cut hopes tick up, and one good catalyst pulls in fast money. Risk is obvious: single-asset biotechs give back gains just as fast on dilution or a trial delay, and you won't see it coming.
Compare it to a peer like Madrigal ($MDGL) — same pattern, giant pops on data, then long grind. I'd rather watch the volume than chase the first green candle.